Haemonetics Corporation (HAE) is a publicly traded Healthcare sector company. As of July 28, 2026, HAE trades at $82.58 with a market cap of $3.63B and a P/E ratio of 40.23. HAE moved +3.29% today. Year to date, HAE is +2.98%; over the trailing twelve months it is +10.55%. Its 52-week range spans $47.32 to $87.32. Analyst consensus is buy with an average price target of $78.71. Rallies surfaces HAE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
9 analysts cover HAE: 0 strong buy, 6 buy, 3 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $78.71.
| Metric | Value |
|---|---|
| Price | $82.58 |
| Market Cap | $3.63B |
| P/E Ratio | 40.23 |
| EPS | $2.06 |
| Dividend Yield | 0.00% |
| 52-Week High | $87.32 |
| 52-Week Low | $47.32 |
| Volume | 673.44K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.33B |
| Net Income | $97.31M |
| Gross Margin | 59.04% |
9 analysts cover HAE: 0 strong buy, 6 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $78.71.